Last reviewed · How we verify
NCT06564259
Relationship Between Serum β2-Microglobulin and Infiltration of CD8+ in the Tumor Tissue of Hodgkin's Lymphoma Patients
trial in Hodgkin Lymphoma in 144 participants. Completed in 15 August 2024.
15 August 2024
Quick facts
| Lead sponsor | Tishreen University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 144 |
| Start date | 4 January 2024 |
| Primary completion | 15 August 2024 |
| Estimated completion | 15 August 2024 |
| Sites | 1 location across Syria |
Conditions studied
- Hodgkin Lymphoma — all drugs for Hodgkin Lymphoma →
Sponsor
Tishreen University
Who can join
Eligibility, any sex, with Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In newly diagnosed Hodgkin lymphoma patients, pre-treatment Beta-2 Microglobulin (B2M) levels will be measured. A thorough baseline assessment will be performed using CT imaging, and tumor tissue samples will be collected for Immunohistochemical (IHC) analysis to quantify CD8+ cell infiltration. Patients will be closely monitored throughout their treatment, with a follow-up CT scan at the end of therapy to evaluate therapeutic response. This study aims to investigate the correlation between pre-treatment B2M levels and CD8+ immune cell infiltration in tumor tissues, assessing their potential as predictive markers for chemotherapy response.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06564259
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT06176690 — Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · Phase 1 · recruiting
- NCT07002216 — BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma · Phase 2 · recruiting
Other Tishreen University trials
Trials by the same sponsor.
- NCT07350421 — The Effectiveness of Inhaled Salbutamol in the Management of Transient Tachypnea of the Newborn(TTN) · NA · not yet recruiting
- NCT07270042 — Evaluation the Efficacy of Zinc on Botulinum Toxin A Injection · NA · not yet recruiting
- NCT07099261 — A Comparative Clinical Study to Evaluate Crowns Designed by Artificial Intelligence Versus Crowns Designed Traditional D · NA · not yet recruiting
- NCT07467759 — Benzydamine for Radiation-Induced Oral Mucositis in Patients Receiving High-Dose Radiotherapy · Phase 4 · completed
- NCT07095946 — Effectiveness of Intraligament vs IANB Anesthesia in Children Using Electronic Syringe · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06564259 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tishreen University
- Last refreshed: 21 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06564259.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing